Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12

Friday, November 6, 2009 General News
Email Print This Page Comment
Font : A-A+



POINT RICHMOND, Calif., Nov. 5 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it will host a webcast and teleconference with management to discuss third quarter 2009 financial results on Thursday, November 12, 2009, at 5:00 p.m. Eastern Standard Time. Financial results for the third quarter ended September 30, 2009 will be released earlier that afternoon.

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website beginning shortly after the conclusion of the call through November 27, 2009.

A telephone replay of the conference call will be available beginning shortly after the conclusion of the call through November 27, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 2918743.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. For further information, please visit the company's website at: www.transcept.com.

Conference Call Information Date: Thursday, November 12, 2009 Time: 5:00 p.m. EST Dial-in (U.S.): 877-874-1589 Dial-in (International): 719-325-4805

SOURCE Transcept Pharmaceuticals, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook